As blocking IL-4 and IL-13 does not influence eosinophil maturation and release from the bone marrow, dupilumab likely traps eosinophils in the blood compartment, which in some patients will manifest eosinophilia [49,50]. The gene discussed is IL4; the disease is Increased total eosinophil count.